Indications
Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.
Composition
- Active substance
- cladribine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Mavenclad
- Active substance
- cladribine
- ATC code
- L04AA40
- Therapeutic area
- Multiple Sclerosis
- Marketing authorisation holder
- Merck Europe B.V.
- Status
- Authorised
- EU authorisation
- 22 Aug 2017